A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production

Journal of Immunology

Volumn 160, Issue 8, 1998, Pages 4098-4103

  Pender, Sylvia L F ^a   Fell, John M E ^b   Chamow, Steven M ^c   Ashkenazi, Avi ^c   MacDonald, Thomas T ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOADHESIN; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; LECTIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; NEUTRALIZING ANTIBODY; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME SYNTHESIS; EXPLANT; FETUS; HUMAN; HUMAN TISSUE; INTESTINE INJURY; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD; CULTURE TECHNIQUES; FETUS; HUMANS; IMMUNOGLOBULIN G; INTESTINAL MUCOSA; METALLOENDOPEPTIDASES; ORGAN CULTURE TECHNIQUES; POKEWEED MITOGENS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 0032522666     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Beutler, B., and A. Cerami. 1989. The biology of cachectin/TNF-a primary mediator of the host response. Annu. Rev. Immunol. 7:625.
2. Beutler, B., and G. E. Grau. 1993. Tumor necrosis factor in the pathogenesis of infectious diseases. Crit. Care Med. 21:S423.
3. Weil, D. 1992. What's new about tumor necrosis factors? Eur. Cytokine Network 3:347.
4. Murch, S. H., V. A. Lamkin, M. O. Savage, J. A. Walker-Smith, and T. T. MacDonald. 1991. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32:913.
5. Murch, S. H., C. P. Braegger, J. A. Walker-Smith, and T. T. MacDonald. 1994. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 35:715.
6. Breese E. J., C. A. Michie, S. W. Nicholls, S. H. Murch, C. B. Williams, P. Domizio, J. A. Walker-Smith, and T. T. MacDonald. 1994. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106:1455.
7. Braegger, C. P., S. Nicholls, S. H. Murch, S. Stephens, and T. T. MacDonald. 1992. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89.
8. Reinecker, H. C., M. Steffen, T. Witthoeft, I. Pflueger, S. Schreiber, R. P. MacDermott, and A. Raedler. 1993. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 94:174.
9. van Deventer, S. J. H. 1997. Tumor necrosis factor and Crohn's disease. Gut 40:443.
10. van Dullemen, H. M., S. J. van Deventer, D. W. Hommes, H. A. Bijl, J. Jansen, G. N. Tytgat, and J. Woody. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129.
11. Targan, S. R., S. B. Hanauer, S. J. H. van Deventer, L. Mayer, D. H. Present, T. Braakman, K. L. DeWoody, T. F. Schaible, and P. J. Rutgeerts. 1997. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N. Engl. J. Med. 337:1029.
12. Rutgeerts, P., G. D'Haens, S. J. H. van Deventer, D. H. Present, L. Mayer, S. B. Hanauer, T. A. J. Braakman, K. L. DeWoody, T. F. Schaible, and S. R. Targan. 1997. Retreatment with anti-TNF-α chimeric Ab (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology 112 (Suppl.):A1078.
13. Stack, W. A., S. D. Mann, A. J. Roy, P. Heath, M. Sopwith, J. Freeman, G. Holmes, R. Long, A. Forbes, M. A. Kamm, and C. J. Hawkey. 1997. Randomised control trial of CDP571 antibody to tumor necrosis factor-α in Crohn's disease. Lancet 349:521.
14. Pender, S. L. F., P. Lionetti, S. H. Murch, N. C. Wathan, and T. T. MacDonald. 1996. Proteolytic degradation of intestinal mucosal extracellular matrix after lamina propria T cell activation. Gut 39:284.
15. Pender, S. L. F., S. P. Tickle, A. J. P. Docherty, D. Howie, N. C. Wathen, and T. T. MacDonald. 1997. A major role for matrix metalloproteinases in T cell injury in the gut. J. Immunol. 158:1582.
16. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157:1261.
17. Parronchi, P., P. Romagnani, F. Annunziato, S. Sampognaro, A. Becchio, L. Giannarini, E. Maggi, C. Pupilli, F. Tonelli, and S. Romagnani. 1997. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J. Pathol. 150:823.
18. Ashkenazi, A., S. A. Marsters, D. J. Capon, S. M. Chamow, I. S. Figari, D. Pennica, D. V. Goeddel, M. A. Palladino, and D. H. Smith. 1991. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc. Natl. Acad. Sci. USA 88:10535.
19. Loetscher, H., R. Gentz, M. Zulauf, A. Lustig, H. Tabuchi, E. J. Schlaeger, M. Brockhaus, H. Gallati, M. Manneberg, and W. Lesslauer. 1991. Recombinant 55-kDa tumor necrosis factor (TNF) receptor: stoichiometry of binding to TNF-α and TNF-β and inhibition of TNF activity. J. Biol. Chem. 266:18324.
20. Jin, H., R. Yang, S. A. Marsters, S. A. Bunting, F. M. Wurm, S. M. Chamow, and A. Ashkenazi. 1994. Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody. J. Infect. Dis. 170:1323.
21. Haak-Frendscho, M., S. A. Marsters, J. Mordenti, S. Brady, N. A. Gillett, S. A. Chen, and A. Ashkenazi. 1994. Inhibition of TNF by a TNF receptor immunoadhesin: comparison with an anti-TNF monoclonal antibody. J. Immunol. 152:1347.
22. MacDonald, T. T., and J. Spencer. 1988. Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine. J. Exp. Med. 167:1341.
23. Lionetti, P., E. Breese, C. P. Braegger, S. H. Murch, J. Taylor, and T. T. MacDonald. 1993. T-cell activation can induce either mucosal destruction or adaptation in cultured human fetal small intestine. Gastroenterology 105:373.
24. Jung, H. C., L. Eckmann, S. K. Yang, A. Panja, J. Fierer, E. Morzycka-Wroblewska, and M. F. Kagnoff. 1995. A distant array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J. Clin. Invest. 95:55.
25. Targan, S. R., R. L. Deem, M. Liu, S. Wang, and A. Nel. 1995. Definition of a lamina propria T cell responsive state: enhanced cytokine responsiveness of T cells stimulated through the CD2 pathway. J. Immunol. 154:664.
26. Rugtveit, J., E. M. Nilsen, A. Bakka, H. Carlsen, P. Brandtzaeg, and H. Scott. 1997. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 112:1493.
27. Spencer, J., T. T. MacDonald, and P. G. Isaacson. 1987. Heterogeneity of non-lymphoid cells expressing HLA-D region antigens in human fetal gut. Clin. Exp. Immunol. 67:415.
28. Beil, W. J., P. F. Weller, M. A. Peppercorn, S. J. Galli, and A. M. Dvorak. 1995. Ultrastructural immunogold localization of subcellular sites of TNF-a in colonic Crohn's disease. J. Leukocyte Biol. 58:284.
29. Sun, X. M., and W. Hsueh. 1988. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J. Clin. Invest. 81:1328.
30. Sun, X., M. S. Caplan, and W. Hsueh. 1994. Tumor necrosis factor and endotoxin synergistically activate intestinal phospholipase A2 in mice: role of endogenous platelet activating factor and effect of exogenous platelet activating factor. Gut 35:215.
31. Abreu-Martin, M. T., A. Vidrich, D. H. Lynch, and S. R. Targan. 1995. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-α and ligation of Fas antigen. J. Immunol. 155:4147.
32. Hiribarren, A., M. Heyman, A. L'Helgouac'h, and J. F. Desjeux. 1993. Effect of cytokines on the epithelial function of the human colon carcinoma cell line HT29 c1 19A. Gut 34:616.
33. Haraldsen, G., D. Kvale, B. Lien, I. N. Farstad, and P. Brandtzaeg. 1996. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (ICAM-1) in human microvascular endothelial cells. J. Immunol. 156:2558.
34. Dayer, J. M., B. Beutler, and A. Cerami. 1985. Cachetic/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. 162:2163.
35. Meikle, M. C., S. J. Atkinson, R. V. Ward, G. Murphy, and J. J. Reynolds. 1989. Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. J. Periodontal. Res. 24:207.
36. Ito, A., T. Sato, T. Iga, and Y. Mori. 1990. Tumor necrosis factor bifunctionally regulates matrix metalloproteinase and tissue inhibitor of metalloproteinase (TIMP) production by human fibroblasts. FEBS Lett. 269:93.
37. Jasser, M. Z., P. G. Mitchell, and H. S. Cheung. 1994. Induction of stromelysin-1 and collagenase synthesis in fibrochondrocytes by tumor necrosis factor-α. Matrix Biol. 14:241.
38. Galis, Z. S., M. Muszynski, G. K. Sukhova, E. Simon-Morrissey, and P. Libby. 1995. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann. N.Y. Acad. Sci. 748:501.
39. Mahida, Y. R., K. Wu, and D. P. Jewell. 1989. Enhanced production of interleukin-1β by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn's disease. Gut 30:835.
40. Cominelli, F., C. C. Nast, A. Duchini, and M. Lee. 1992. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 103:65.
41. Casini-Raggi, V., L. Kam, Y. J. Chong, C. Fiocchi, T. T. Pizarro, and F. Cominelli. 1995. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease: a novel mechanism of chronic intestinal inflammation. J. Immunol. 154:2434.
42. Hyams, J. S., J. E. Fitzgerald, N. Wyzga, R. Muller, W. R. Treem, C. J. Justinich, and D. L. Kreutzer. 1995. Relationship of interleukin-1 receptor antagonist to mucosal inflammation in inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 21:419.
43. Sartor, R. B. 1995. Current concepts of the etiology and pathogenesis of ulecartive colitis and Crohn's disease. Gastroenterol. Clin. North Am. 24:475.